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Abstract: T-cell non-Hodgkin lymphoma is a heterogeneous disease ranging from malignancies
arising from thymic T cells halted in development, through to mature, circulating peripheral T cells.
The latter cases are diagnostically problematic with many entering the category of peripheral T-cell
lymphoma, not otherwise specified (PTCL, NOS). Anaplastic large cell lymphoma (ALCL) is one of
the exceptions to this whereby aberrant expression of anaplastic lymphoma kinase (ALK) and the
distinctive presence of cell surface CD30 places this entity in its own class. Besides the expression
of a well-studied oncogenic translocation, ALCL, ALK+ may also have a unique pathogenesis
with a thymic origin like T lymphoblastic lymphoma but a peripheral presentation akin to PTCL.
This perspective discusses evidence towards the potential origin of ALCL, ALK+, and mechanisms
that may give rise to its unique phenotype.
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1. Introduction
Systemic anaplastic large cell lymphoma (ALCL) is a relatively rare malignancy of T cells and is
sub-divided dependent on expression of anaplastic lymphoma kinase (ALK) creating ALCL, ALK+ and
ALCL, ALK− sub-classes [1,2]. The former is largely diagnosed in younger patients, has a good
prognosis and is addicted to ALK, whilst the latter is seen in an older patient demographic with a
relatively poor prognosis and a scarcity of driving oncogenic events. ALCL can also present as a
cutaneous form or in the context of breast implants, both being ALK negative [3,4]. Given the various
presenting forms and differing prognoses, it makes sense that the ALCL sub-types should form distinct
disease categories but also raises the issue of whether they are the consequence of a shared pathogenesis
and origin. Indeed, mounting evidence points towards a thymic or more primitive haemopoietic origin
for ALCL, ALK+ with perhaps in utero derivation akin to some childhood leukaemia, in contrast
to a putative peripheral and adulthood initiation of ALCL, ALK− [5–7]. However, it is likely that
there are overlapping mechanisms of pathogenesis given their shared and unique histopathology.
This perspective will discuss and present evidence eluding towards the aforementioned mechanisms,
comparing and contrasting disease processes with reference to the relative merits of model systems
and techniques that have been employed to divulge this information.
2. T-Cell Development and the Origins of ALCL
Solid cancers of T cells are considered as having either mature or immature origins dependent on
a number of diagnostic factors, ultimately presenting as either immature or mature T-cell lymphoma
located in the thymus or at nodal/extranodal sites in the periphery. A thymic origin is reserved for
T lymphoblastic lymphoma (T-LBL) whereby tumours can present in the thymus and/or periphery
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and may even have a leukaemic presentation, but T-cell receptor (TCR) rearrangements are in all cases
supportive of a primitive origin [8–10]. In contrast, ALCL is considered a peripheral T-cell lymphoma
due to the expression of mature, activated T cell markers as well as largely peripheral presentation
of tumours. However, in the absence of ALK expression, diagnosis can be difficult and may overlap
with peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS) although expression of CD30
and key histological features enable better distinction as can the gene expression profile [11–13].
Regardless, broadly speaking, if a T-cell malignancy shares features with an immature T cell, it is called
a lymphoblastic lymphoma, thought to arise from thymic T cells with all others presumed to derive
from peripheral T cells. Whilst this is an easy way to define malignancies, one must consider that the
final form in which a malignancy presents may mask its natural history.
2.1. T-Cell Receptor Gene Rearrangement Status Presents a History and Time Stamp of Thymocyte Development
Like B cells, T cells uniquely rearrange antigen receptors which provide a tattoo of their
progression through the thymus; thymic progenitors rearrange the TCR genes in a temporal and
location-specific manner on encountering neighbouring, thymic-resident cells presenting antigen in an
MHC-restricted manner [10,14]. Ultimately, successful rearrangement leads to the emergence of T cells
from the thymus that recognise foreign antigens presented together with MHC, but not self-proteins.
Most commonly, T cells leave the thymus with rearranged α and β chains to become αβ T cells,
whilst some emerge as γδ T cells having not progressed to rearrangement of α and β chain genes.
As such, T cells only emerge into the periphery if these processes are successful except in cases where
thymocyte survival is subverted by the presence of TCR-bypass events. As such, analysis of TCR
rearrangement status in malignancies of these cells can provide clues as to their origin and the stage of
T cell development they reached prior to transformation [10].
2.2. TCR Rearrangements in ALCL are Suggestive of Stalled Thymocyte Development of Apparently Mature T
Cells Indicative of a Primitive T-Cell Origin for this Malignancy
ALCL is considered a T-cell lymphoma even though tumour cells often lack expression of cell
surface proteins indicative of this cellular phenotype. However, molecular TCR rearrangements
are detectable in the tumour cells supportive of a T-cell origin. Indeed, an in-depth analysis of
these molecular rearrangements in ALCL, ALK+ has highlighted some unusual T cell receptor (TR)
genotypes not normally permissive of thymocyte survival and T cell development [6]: an analysis
of 57 ALCL showed that whilst 56% of tumours display apparently normal TRab rearrangements,
82% of these 56% do not have major clonal TRb rearrangements. In addition, 11% of tumours only
have TRg rearrangements, and 14% have no TR rearrangements at all consistent with a null cell
immunophenotype. The remaining 19% could potentially originate in normal γδ T cells with apparently
normal TRg and TRd rearrangements. Overall, these data are supportive of a consistent lack of major
clonal TRb rearrangements in ALCL, suggesting that thymic processes may have been perturbed in
these patients; expression of a strong survival factor may allow T cells without survival-permissive
TCR to develop and escape into the periphery. Indeed, in a murine model, NPM-ALK has the
capacity to enable this, whereby, even in the absence of RAG, the enzyme responsible for this
process, T-cell development appears normal [6]. This is perhaps not surprising given the plethora
of mitogenic/survival signaling pathways known to be activated by this oncogene including those
normally active as a consequence of TCR engagement [15,16].
Intriguingly and together with the detection of NPM-ALK in cord blood of 2% of the healthy
population [17], these data raise the possibility that like T-LBL, ALCL is also a malignancy arising
in thymocytes but in the latter case, thymocytes that can still apparently progress through T-cell
developmental stages in the absence of TR rearrangement [6]. Alternatively, the translocation may be
induced at a more primitive stage, as suggested by the findings in cord blood although this then raises
the question as to why NPM-ALK is restricted to T-cell lymphoma as opposed to any other malignancy
derived from haemopoietic stem cells.
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3. NPM-ALK Induced Signaling Events May Counteract Thymic Beta-Selection
NPM-ALK is a hyperactive tyrosine kinase by virtue of its ability to dimerise and subsequently
autophosphorylate on tyrosine residues [18]. These then form docking sites for SH2 domain containing
proteins activating a plethora of signaling pathways largely including those expected of a hyperactive
intracellular kinase [19]. For example, signaling through PI 3-Kinase-AKT, mTOR, RAS MAP Kinase,
JNK-Jun, AP-1, JAK/STAT, and PLCg/Ca2+ pathways and transcription factors is well-established,
all pathways with the potential to drive proliferation and promote cell survival, two key hallmarks
of malignancies [15,20–31]. The first key checkpoint in thymic development is β-selection, a process
whereby the absence of a signal emanating from an engaged pre-TCR leads to cell death. Cell survival
is dependent on activation of Notch 1, and NPM-ALK is able to activate signaling via this pathway in
murine thymocytes at the DN2/3 stages of thymic development [6]. Indeed, NPM-ALK expression
in thymocytes also leads to the upregulation of CD98 and CD71, nutrient transporters required for
massive cellular proliferation associated with post-β-selection thymocytes [6]. It follows that Notch 1
is expressed on the surface of established ALCL tumour cells, possibly a remnant of their time in the
thymus [32]. Notch 1 is also known to play a role in mature, peripheral T cells [33], but the relative
importance of Notch 1 to thymic development is underscored by the detection of Notch 1 mutations in
thymic-derived T-ALL [34].
4. Accounting for the Activated Cellular Phenotype of ALCL
ALCL has an unusual presentation with an immunophenotype that does not place it neatly
into any specific T cell subset. In general, most tumours are negative for CD8 but produce cytotoxic
proteins such as perforin and Granzyme B, and whilst being largely CD4 positive, they lack expression
of a TCR/CD3 [4,35]. Regardless, expression of CD30 is consistent but does not confer a lineage
identity to the cells beyond their apparent activation status [4,36]. Indeed, tumour cells also express the
epithelial cell protein EMA (MUC1), expression of which has also been linked to activated T cells [37,38].
However, as mentioned above, if NPM-ALK can substitute for pre-TCR signaling in thymocytes, then
it can also potentially mimic signals indicative of an activated status normally observed on engagement
of a full TCR [15]. Beyond these lineage-defining cell surface proteins, molecular TCR rearrangements
are supportive of a T-cell status [6].
4.1. Is NPM-ALK, the Tumour Microenvironment, and/or the Cell of Origin Responsible for the
Immunophenotype of Cells in ALCL, ALK+?
It is possible to garner more information on a cell’s identity by its secretome, particularly in
the T cell lineage, whereby distinct cytokines can both induce a skew towards a specific effector
cell type and likewise, when secreted can divulge the identity of the producing cell, as can the
distinct profile of transcription factors active within it. Hence, even though primitive forms of
gene expression profiling have been unable to align ALCL with either cytotoxic or helper T cells,
some enriched gene sets have highlighted specific associations [36]. For example, a Th17 profile could
be extracted whereby expression of a set of genes including IL17A, IL17F, IL26, IL22, and RORg was
noted [12]. Interestingly, IL22 and IL17 are also present in the circulation of ALCL, ALK+ patients [39].
Naturally, immune cells are heavily influenced by their microenvironment and cytokines within
it that may have stimulatory effects on them. A Th17 skew is induced by IL6 in the presence
of TGFb, and it follows that IL6 is produced in an autocrine manner by ALCL in an NPM-ALK
dependent-manner via STAT3 and miR135b [40]. This oncogene-driven pathway was also shown to
be responsible for the production of IL17A and IL17F, suggesting that the Th17 phenotype could be
attributable to NPM-ALK expression and activity rather than microenvironmental factors or even
cell of origin [40]. Furthermore, perforin and Granzyme B are produced in an NPM-ALK-dependent
manner again providing evidence towards a cell phenotype modelled by the driving oncogene [40,41].
Of note, in the study by Matsuyama et al, the Th17-associated transcription factor RORg was not
dependent on miR-135b activity although it remains to be determined whether it is expressed in an
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NPM-ALK-dependent manner [40]. Altogether, these data suggest that the immunophenotype of
ALCL, ALK+ is not incompatible with a thymic origin, whereby NPM-ALK is able to drive thymic
development in the absence of complete and survival-compatible TCR rearrangements to allow cells
to ‘mature’, enter the periphery, and appear to be of a Th17/cytotoxic T-cell origin (Figure 1).
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subset. Whether these proteins are induced by driving oncogenic events and/or the tumour 
microenvironment remains to be determined, but in the case of ALCL, ALK+ at least, it is clear that 
NPM-ALK is capable of partially mimicking the immunophenotype of multiple T-cell subsets. CLP = 
common lymphoid progenitor; DN = double negative; DP = double positive; TEC = Thymic Epithelial 
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is upregulated in ALCL, ALK−, a miR that is known to induce a Th17 cell skew, and despite some 
cases displaying JAK1/STAT3 mutations, cells remain cytokine-dependent [42–44]. Whilst it can be 
difficult to tease apart mechanisms specific to ALCL, ALK− due to a relative paucity of model 
systems, the more recent description of breast-implant-associated ALCL (BIA-ALCL) has provided 
more clues [3,45,46]. Cell lines derived from BIA-ALCL and cutaneous ALCL also produce IL17A, 
IL17F, and IL6, but IL10, IL13, IL21, IFNg, GM-CSF, IL7, and TNFa are also produced, cytokines that 
are attributable to other helper T cell subsets [44]. However, the presence of activating JAK/STAT 
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are also associated with activating mutations/translocations in JAK/STAT family proteins [49] and 
4% of cutaneous ALCL with TYK2 fusion proteins [50]. Could it be the case that each individual case 
of ALCL has a unique profile that is shaped not only by the intrinsic oncogenic events but also its 
particular microenvironmental circumstance? Th17 cells are known to react to large extracellular 
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Bacterial biofilms have been reported in the context of BIA-ALCL, which fits with this hypothesis and 
would also give rise to an activated cell surface phenotype as exemplified by CD30 expression [51]. 
Figure 1. The unique immunophenotype of ALCL makes it difficult to assign an exact cellular
origin with gene expression studies unable to divulge a distinct cell of origin. The presence of
aberrant TCR rearrangements suggests subversion of thymic development mediated by NPM-ALK
in a Notch1-dependent manner proposing an early origin for this largely paediatric cancer.
However, tumour cells express and secrete proteins (denoted by yellow boxes) that inhibit assignment
to an exact T cell subset. Whether these proteins are induced by driving oncogenic events and/or the
tumour microenviron ent remains to be determined, but in the case of ALCL, ALK+ at least, it is clear
that NPM-ALK is capable of partially mimicking the immunophenotype of multiple T-cell subsets.
CLP = com on lymphoid progenitor; DN = double negative; DP = double positive; TEC = Thymic
Epithelial Cell; ILC = Innate Lymphoid Cell; HR = Aryl Hydrocarbon Receptor; Th = helper T cell;
Tc = cytotoxic T cell; Treg = regulatory T cell; Tfh = follicular helper T cell; TR = T cell receptor.
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is re late in ALCL, ALK−, a miR that is known to induce a Th17 cell skew, and despite some cases
displaying JAK1/STAT3 mutations, cells remain cytokine-dependent [42–44]. Whilst it can be difficult
to tease apart mechanisms specific to ALCL, ALK− due to a relative paucity of model systems, the more
recent description of breast-implant-associated ALCL (BIA-ALCL) has provided more clues [3,45,46].
Cell lines derived from BIA-ALCL and cutaneous ALCL also produce IL17A, I 17F, and IL6, but IL10,
I 13, IL21, IFNg, GM-CSF, IL7, and T Fa are also produce , cytokines that are attributable to ot er
helper T cell subsets [44]. However, the presence of activating JAK/STAT mutations in BIA-ALCL
ay also be driving this particular secretome [47,48]. Indeed, ALCL, ALK− are also associated with
activating mutations/translocations in JAK/STAT family proteins [49] and 4% of cutaneous ALCL with
TYK2 f sion proteins [50]. Could it be the case that each individual case of ALCL has a unique profile
that is shaped not only by the intrinsic oncogenic events but also its particular microenvironmental
circumstance? Th17 cells are known to react to large extracellular pathogens such as bacteria, whereas
Cancers 2017, 9, 141 5 of 8
Th1 cells, for example, respond to intracellular pathogens. Bacterial biofilms have been reported in
the context of BIA-ALCL, which fits with this hypothesis and would also give rise to an activated cell
surface phenotype as exemplified by CD30 expression [51]. In this regard, ALCL have been reported
to be associated with tick and other insect bites, which could lead to infection [52,53].
4.3. Does Infection Play a Role in ALCL Lymphomagenesis and Cellular Immunophenotype?
The fact that the tumour cells appear to be activated by virtue of CD30 expression yet not
having a gene expression profile compatible with an activated CD30+ T cell hints towards an
oncogene-driven rather than environmental event [36]. Indeed, CD30 expression has been reported
as an NPM-ALK driven JunB-induced event in ALCL [54]. Whilst this suggests that activation
is not a consequence of antigenic stimulation, as mentioned previously, ALCL, ALK+ have been
reported in the context of tick and other insect bites although in some cases, ALCL, ALK+ do not
have the ability to express a functional TCR and proximal signaling proteins are silenced in an
epigenetic manner [6,35,52,53,55]. However, some lymphoid cells exist that respond to inflammatory
environments in a receptor-independent manner. These cells are the relatively recently described
innate lymphoid cells (ILCs) of which there are three distinct groups with origins in common lymphoid
progenitors. Of interest, Group 3 ILCs share many facets with Th17 cells: expression of RORg and
AHR as well as production of IL17 and IL22 [56]. It may therefore be the case that incipient ALCL
without functional TCR responds to infections akin to Group 3 ILCs, whereas those with a TCR act as
Th17 or as another T-cell subset. In the latter case, the TCR is subsequently downregulated as results
from a murine model show that a combination of signaling through a TCR and NPM-ALK are not
compatible with lymphomagenesis, and the TCR is rarely expressed in primary ALCL [6,35].
5. Conclusions
ALCL and other T-cell lymphomas remain malignancies of unknown origins and causes with few
aetiological associations. This is largely due to a lack of model systems and a relatively scarcity of
patient material from which to divulge information. However, marrying together clinical observations
with laboratory studies has allowed some progress to be made.
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